A CI team can know a drug well and still miss the program that matters to its decision. The approved use sits on the watchlist. A Phase 3 trial in an earlier disease stage is attached to the same drug name, and the search never returns it as a separate competitor.
That gap usually starts with how source documents become searchable records: which sources a provider collects, which details it stores and how often it reviews an entry. When a record loses the detail a question needs, an analyst rebuilds it by hand, and the business pays for the same information a second time.
This white paper traces where those gaps appear in a live assessment, what they cost a CI team and what changes when checked facts carry forward from one deliverable to the next.
Download the White Paper
Platform Coverage
Clinical trials indexed
Where CI assessments lose detail, and what it costs to recover it
About Ferma
Ferma is the AI-native intelligence platform for life sciences, a business unit of ZoomRx, backed by 15+ years of life sciences domain expertise. Ferma's Agentic Workflows turn the research, synthesis and delivery of decision-ready intelligence into finished, fully cited deliverables for Competitive Intelligence, BD&L, New Product Planning and beyond.
Coverage spans clinical trials, conference records, regulatory filings, publications and native-language China sources. SOC 2 Type II certified.